Ardent Health Partners' stock fell sharply intraday, declining by 5.08%.
The drop followed news that Leerink lowered its price target on the company's shares to $15 from $16, though the firm maintained its Outperform rating on the stock. Analyst price target revisions are closely watched by investors and can trigger immediate market reactions.